Reader Comments
Post a new comment on this article
Post Your Discussion Comment
Please follow our guidelines for comments and review our competing interests policy. Comments that do not conform to our guidelines will be promptly removed and the user account disabled. The following must be avoided:
- Remarks that could be interpreted as allegations of misconduct
- Unsupported assertions or statements
- Inflammatory or insulting language
Thank You!
Thank you for taking the time to flag this posting; we review flagged postings on a regular basis.
closeFDA reports and publication bias
Posted by plosmedicine on 31 Mar 2009 at 00:30 GMT
Author: Fredric Cohen
Position: President
Institution: Pharma Growth Strategies LLC
E-mail: fred@pharmaweblog.com
Submitted Date: September 24, 2008
Published Date: September 29, 2008
This comment was originally posted as a “Reader Response” on the publication date indicated above. All Reader Responses are now available as comments.
Lee et al are correct that current regulations will not ensure an absence of publication bias for US-approved drugs, as the minimum "basic results" required to be disclosed are not necessarily sufficient for making independent inferences of study results.
The logical solution is for legislators to mandate disclosure of complete study reports on the web immediately following marketing approval. The reports could be posted on a public site that allows for "peer review," much like PLoS offers this commenting opportunity.